M. Rader

发表

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

F. Saad, A. Stopeck, D. Yardley, 2012, European journal of cancer.

Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices

B. Ding, H. Ozer, M. Rader, 2010 .

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.

S. Wadler, E. Schwartz, L. Itri, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory Pseudotumor of Spleen

P. Wiernik, N. Becker, M. Rader, 1990, Cancer.

B. Ding, H. Ozer, S. Noga, 2007 .

Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.

B. Ding, H. Ozer, S. Noga, 2007, The oncologist.

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.

R. Neuwirth, K. Venkatakrishnan, S. Ramalingam, 2009, Clinical therapeutics.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

M. Carducci, Janet E Brown, K. Fizazi, 2011, The Lancet.

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

M. Carducci, S. Oudard, Janet E Brown, 2015, European urology.

Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.

M. Carducci, S. Oudard, Janet E Brown, 2012 .

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

A. Stopeck, David Henry, M. Danese, 2012, Journal of medical economics.

Granulocyte Colony-Stimulating Factor Use in Patients With Chemotherapy-Induced Neutropenia : Review

M. Rader, 2017 .

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

C. Goessl, M. Rader, Z. Cong, 2012, Journal of managed care pharmacy : JMCP.

Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.

S. Novello, M. Krzakowski, T. Ciuleanu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials

D. Stull, D. Revicki, D. Tomita, 2012, Quality of Life Research.

Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.

M. Rader, 2006, Oncology.